Pfizer Inc has completed its acquisition of Metsera, Inc., a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and cardiometabolic diseases.

“This strategic milestone represents more than a transaction—it's a deliberate investment in the future of medicine. By acquiring Metsera, we are directing our resources toward one of the most impactful and high-growth therapeutic areas and positioning ourselves to define it. We look forward to combining Metsera’s innovative portfolio with our global development, manufacturing and commercial infrastructure. Working with our talented new colleagues from Metsera, we will advance our shared goal of accelerating and bringing these important candidate therapies to patients around the world,” said Albert Bourla, Chairman and Chief Executive Officer (CEO), Pfizer.

Through this acquisition, Pfizer has added a portfolio of promising therapeutic candidates that are complementary to Pfizer’s internal medicine pipeline, including MET-097i, a weekly and monthly injectable GLP-1 receptor agonist about to begin Phase 3 development; MET-233i, a monthly amylin analog candidate being evaluated as monotherapy and in combination with MET-097i in Phase 1 development; an oral GLP-1 RA candidate in Phase 1 development; and additional preclinical nutrient-stimulated hormone therapeutics.

The transaction is expected to be dilutive through 2030, primarily to enable further investment in several promising late-stage pipeline candidates. Updated impact to Pfizer’s financial outlook will be provided in conjunction with its 2026 guidance expected later this year.